Evidence map›Paper›PMID 38240887›Full record

ReviewClinical & experimental metastasis2024

miRNAs in pancreatic cancer progression and metastasis.

Ellie T Y Mok, Jessica L Chitty, Thomas R Cox

Open access · hybridAbstract readReview
In one paragraph

Review in Clinical & experimental metastasis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. microRNA-155: a versatile noncoding RNA.Molecular biology reports · 2026
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Challenges of early detection of pancreatic cancer.The Journal of clinical investigation · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ellie T Y MokMatrix & Metastasis Lab, Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.ORCID 0009-0003-7750-3335
Jessica L ChittyMatrix & Metastasis Lab, Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia. j.chitty@garvan.org.au.ORCID 0000-0003-1776-1618
Thomas R CoxMatrix & Metastasis Lab, Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia. t.cox@garvan.org.au.ORCID 0000-0001-9294-1745
Garvan Institute of Medical Research · AU

Funding

Cancer Council NSW RG21-11Cancer Institute NSW CDF171105National Health and Medical Research Council 2000937, 1140125, 1158590, 2013881Perpetual IMPACT IPAP2020/0066Susan G. Komen CCR17483294University of New South Wales University Postrgraduate Award (UPA)
6 · The paper itself

Abstract

Small non-coding RNA or microRNA (miRNA) are critical regulators of eukaryotic cells. Dysregulation of miRNA expression and function has been linked to a variety of diseases including cancer. They play a complex role in cancers, having both tumour suppressor and promoter properties. In addition, a single miRNA can be involved in regulating several mRNAs or many miRNAs can regulate a single mRNA, therefore assessing these roles is essential to a better understanding in cancer initiation and development. Pancreatic cancer is a leading cause of cancer death worldwide, in part due to the lack of diagnostic tools and limited treatment options. The most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), is characterised by major genetic mutations that drive cancer initiation and progression. The regulation or interaction of miRNAs with these cancer driving mutations suggests a strong link between the two. Understanding this link between miRNA and PDAC progression may give rise to novel treatments or diagnostic tools. This review summarises the role of miRNAs in PDAC, the downstream signalling pathways that they play a role in, how these are being used and studied as therapeutic targets as well as prognostic/diagnostic tools to improve the clinical outcome of PDAC.

Indexed as

Carcinoma, Pancreatic DuctalDisease ProgressionGene Expression Regulation, NeoplasticMicroRNAsPancreatic NeoplasmsAnimalsHumansNeoplasm MetastasisSignal TransductionMicroRNAsDiagnosticsmicroRNANovel therapeuticsPancreatic ductal adenocarcinoma

Identifiers

PMID38240887
PMCPMC11213741
OpenAlexW4391027948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.